Standard BioTools Announces Agreement to Sell Microfluidics Business to ARCHIMED
Key Highlights
- ➤Standard BioTools (LAB) agrees to sell Microfluidics business to ARCHIMED
- ➤Transaction expected to close in approximately 30 days, subject to customary conditions
- ➤Microfluidics business remains part of Standard BioTools until closing
- ➤Sale advances Standard BioTools’ previously announced strategic actions
Expert Statements
Michael Egholm, President and Chief Executive Officer of Standard BioTools
“ARCHIMED brings deep healthcare and life sciences expertise, a strong understanding of the market and the resources to support the business’ next chapter. This is a strong outcome for our employees and our customers, and we believe the business will continue to grow and innovate under new ownership. This transaction marks another important step in the strategic actions we laid out for Standard BioTools and our shareholders.”
BOSTON, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced it has entered into a definitive agreement to sell its Microfluidics business to ARCHIMED (“ARCHIMED”), a leading investment firm focused exclusively on healthcare industries.
Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools, said, “ARCHIMED brings deep healthcare and life sciences expertise, a strong understanding of the market and the resources to support the business’ next chapter. This is a strong outcome for our employees and our customers, and we believe the business will continue to grow and innovate under new ownership. This transaction marks another important step in the strategic actions we laid out for Standard BioTools and our shareholders.”
Get started
Create a free account to read the full story.